<DOC>
	<DOC>NCT01984606</DOC>
	<brief_summary>The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic control. The study will assess non-inferiority of empagliflozin to sitagliptin with regards to HbA1c.</brief_summary>
	<brief_title>Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criteria: Inclusion criteria: Diagnosis of type 2 diabetes mellitus. Male and female patients on diet and exercise regimen who are: Treatmentnaïve, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomisation. or Pretreated with immediate release metformin unchanged for 10 weeks prior to randomisation. Minimum dose for metformin: &gt;=1500 mg/day or maximum tolerated dose or maximum dose according to local label. HbA1c of &gt;= 7.5 % and &lt;= 10.5 % at Visit 1 and 3. Age &gt;= 18 yrs. Exclusion criteria: Uncontrolled hyperglycaemia with a glucose level &gt;270 mg/dL (&gt;15 mmol/L) after an overnight fast during dose stabilisation (if applicable) and/or placebo runin. Any other antidiabetic drug within 12 weeks prior to randomisation (applicable to treatmentnaïve patients). Any other antidiabetic drug within 10 weeks prior to randomisation except metformin (applicable to patients on background treatment with metformin). Acute coronary syndrome (nonSTEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent. Indication of liver disease. Moderate to severe renal impairment. Bariatric surgery within the past two years. Treatment with antiobesity drugs 3 months prior to informed consent. Current treatment with systemic steroids at time of informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>